Skip to main content
Top
Published in: Dermatology and Therapy 10/2022

Open Access 01-09-2022 | Vulgar Psoriasis | Review

Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application

Authors: Morten Praestegaard, Fraser Steele, Nigel Crutchley

Published in: Dermatology and Therapy | Issue 10/2022

Login to get access

Abstract

Topical formulation and delivery technologies for pharmaceutical application should simultaneously address efficacy, safety and convenience of therapy. This has historically proven to be challenging, since formulation features that drive efficacy often have undesirable consequences for safety and convenience and vice versa. Polyaphron dispersion (PAD) technology is a novel topical formulation and drug delivery system developed with the purpose of preserving these key attributes. PAD formulations are typically oil-in-water dispersions consisting of oil droplets encapsulated in a multi-molecular shell structure. This shell structure protects potentially unstable active molecules solubilized in the oil from hydrolytic degradation. Example data are presented of enhanced drug penetration from PAD formulations, including dermal delivery of calcipotriene, betamethasone dipropionate and tacrolimus as well as ocular delivery of ciclosporin A. Local tolerability is an important safety parameter for topical formulations, where high levels of surfactants can cause skin irritation. In this regard, a key benefit of PAD formulations is the inherent reduced requirement for surfactants to generate stable formulations compared to conventional emulsion systems. Patients with chronic diseases with topical manifestations such as psoriasis or atopic dermatitis have been reported to miss up to 70% of planned topical applications, mainly due to a lack of satisfaction with their therapy. Patients generally prefer light, moisturizing, non-greasy and quickly absorbed vehicles that are simple to use on all body parts. PAD formulations can generally be designed to meet these criteria. In conclusion, PAD technology provides high flexibility in topical drug design and can be applied to several body locations without compromising efficacy, safety or convenience of therapy.
Clinical Trial Register: Clinicaltrials.gov: NCT03802344.
Literature
1.
go back to reference Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9–14.PubMedCrossRef Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9–14.PubMedCrossRef
2.
go back to reference Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6.PubMedCrossRef Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6.PubMedCrossRef
3.
go back to reference Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–13.PubMedCrossRef Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–13.PubMedCrossRef
4.
go back to reference van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197(1):31–6.PubMedCrossRef van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197(1):31–6.PubMedCrossRef
5.
go back to reference Mohammed YH, Moghimi HR, Yousef SA, Chandrasekaran NC, Bibi CR, Sukumar SC, et al. (2017) Efficacy, safety and targets in topical and transdermal active and excipient delivery. In: Dragicevic NI, Maibach H, editors., et al., Percutaneous penetration enhancers drug penetration into/through the skin: methodology and general considerations. Heidelberg: Springer; 2017. p. 369–91. Mohammed YH, Moghimi HR, Yousef SA, Chandrasekaran NC, Bibi CR, Sukumar SC, et al. (2017) Efficacy, safety and targets in topical and transdermal active and excipient delivery. In: Dragicevic NI, Maibach H, editors., et al., Percutaneous penetration enhancers drug penetration into/through the skin: methodology and general considerations. Heidelberg: Springer; 2017. p. 369–91.
6.
go back to reference Lemery E, Briançon S, Chevalier Y, Oddos T, Gohier A, Boyron O, et al. Surfactants have multi-fold effects on skin barrier function. Eur J Dermatol. 2015;25(5):424–35.PubMedCrossRef Lemery E, Briançon S, Chevalier Y, Oddos T, Gohier A, Boyron O, et al. Surfactants have multi-fold effects on skin barrier function. Eur J Dermatol. 2015;25(5):424–35.PubMedCrossRef
7.
go back to reference Mayba JN, Gooderham MJ. A guide to topical vehicle formulations. J Cutan Med Surg. 2018;22(2):207–12.PubMedCrossRef Mayba JN, Gooderham MJ. A guide to topical vehicle formulations. J Cutan Med Surg. 2018;22(2):207–12.PubMedCrossRef
8.
go back to reference Benson HAE, Grice JE, Mohammed Y, Namjoshi S, Roberts MS. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv. 2019;16(5):444–60.PubMedPubMedCentralCrossRef Benson HAE, Grice JE, Mohammed Y, Namjoshi S, Roberts MS. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv. 2019;16(5):444–60.PubMedPubMedCentralCrossRef
9.
go back to reference Cevc G, Mazgareanu S, Rother M, Vierl U. Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. Int J Pharm. 2008;359(1–2):190–7.PubMedCrossRef Cevc G, Mazgareanu S, Rother M, Vierl U. Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. Int J Pharm. 2008;359(1–2):190–7.PubMedCrossRef
10.
go back to reference Hashim PW, Chen T, Hebert AA, Kircik LH. Topical treatment for the management of atopic dermatitis. J Drugs Dermatol. 2019;18(s2):s112–6.PubMed Hashim PW, Chen T, Hebert AA, Kircik LH. Topical treatment for the management of atopic dermatitis. J Drugs Dermatol. 2019;18(s2):s112–6.PubMed
11.
go back to reference Puig L, Carrascosa JM, Belinchon I, Fernandez-Redondo V, Carretero G, Ruiz-Carrascosa JC, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermo-Sifiliograf. 2013;104(6):488–96.CrossRef Puig L, Carrascosa JM, Belinchon I, Fernandez-Redondo V, Carretero G, Ruiz-Carrascosa JC, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermo-Sifiliograf. 2013;104(6):488–96.CrossRef
12.
go back to reference Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221–4.PubMedCrossRef Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221–4.PubMedCrossRef
13.
go back to reference Teixeira A, Teixeira M, Almeida V, Gaio R, Torres T, Magina S, et al. Does the vehicle matter? Real-world evidence on adherence to topical treatment in psoriasis. Pharmaceutics. 2021;13(10):1539.PubMedPubMedCentralCrossRef Teixeira A, Teixeira M, Almeida V, Gaio R, Torres T, Magina S, et al. Does the vehicle matter? Real-world evidence on adherence to topical treatment in psoriasis. Pharmaceutics. 2021;13(10):1539.PubMedPubMedCentralCrossRef
14.
go back to reference Fujimura T, Shimotoyodome Y, Nishijima T, Sugata K, Taguchi H, Moriwaki S. Changes in hydration of the stratum corneum are the most suitable indicator to evaluate the irritation of surfactants on the skin. Skin Res Technol. 2017;23(1):97–103.PubMedCrossRef Fujimura T, Shimotoyodome Y, Nishijima T, Sugata K, Taguchi H, Moriwaki S. Changes in hydration of the stratum corneum are the most suitable indicator to evaluate the irritation of surfactants on the skin. Skin Res Technol. 2017;23(1):97–103.PubMedCrossRef
15.
go back to reference Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017;31(8):1271–84.PubMedCrossRef Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017;31(8):1271–84.PubMedCrossRef
16.
go back to reference Molaei A, Waters KE. Aphron applications—a review of recent and current research. Adv Colloid Interface Sci. 2015;216:36–54.PubMedCrossRef Molaei A, Waters KE. Aphron applications—a review of recent and current research. Adv Colloid Interface Sci. 2015;216:36–54.PubMedCrossRef
17.
go back to reference Ward K, Taylor A, Mohammed A, Stuckey DC. Current applications of colloidal liquid aphrons: predispersed solvent extraction, enzyme immobilization and drug delivery. Adv Colloid Interface Sci. 2020;275: 102079.PubMedCrossRef Ward K, Taylor A, Mohammed A, Stuckey DC. Current applications of colloidal liquid aphrons: predispersed solvent extraction, enzyme immobilization and drug delivery. Adv Colloid Interface Sci. 2020;275: 102079.PubMedCrossRef
18.
go back to reference McNaught AD, Wilkinson A. Compendium of chemical terminology. Hoboken: Blackwell Science; 1997. p. 464. McNaught AD, Wilkinson A. Compendium of chemical terminology. Hoboken: Blackwell Science; 1997. p. 464.
19.
go back to reference Sebba F. Foams and biliquid foams, aphrons. New York: Wiley; 1987. Sebba F. Foams and biliquid foams, aphrons. New York: Wiley; 1987.
20.
go back to reference Yan Y-l, Zhang N-S, Qu C-T, Liu L. Microstructure of colloidal liquid aphrons (CLAs) by freeze fracture transmission electron microscopy (FF-TEM). Colloids Surf A Physicochem Eng Asp. 2005;264(1):139–46.CrossRef Yan Y-l, Zhang N-S, Qu C-T, Liu L. Microstructure of colloidal liquid aphrons (CLAs) by freeze fracture transmission electron microscopy (FF-TEM). Colloids Surf A Physicochem Eng Asp. 2005;264(1):139–46.CrossRef
21.
go back to reference Amiri MC, Woodburn ET. A method for the characterisation of colloidal gas aphron dispersions. Chem Eng Res Des. 1990;68:154–60. Amiri MC, Woodburn ET. A method for the characterisation of colloidal gas aphron dispersions. Chem Eng Res Des. 1990;68:154–60.
22.
go back to reference Bredwell MD, Worden RM. Mass-transfer properties of microbubbles. 1. Experimental studies. Biotechnol Progr. 1998;14(1):31–8.CrossRef Bredwell MD, Worden RM. Mass-transfer properties of microbubbles. 1. Experimental studies. Biotechnol Progr. 1998;14(1):31–8.CrossRef
23.
go back to reference Jauregi P, Mitchell GR, Varley J. Colloidal gas aphrons (CGA): dispersion and structural features. AIChE J. 2000;46(1):24–36.CrossRef Jauregi P, Mitchell GR, Varley J. Colloidal gas aphrons (CGA): dispersion and structural features. AIChE J. 2000;46(1):24–36.CrossRef
24.
go back to reference Namjoshi S, Dabbaghi M, Roberts MS, Grice JE, Mohammed Y. Quality by design: development of the quality target product profile (QTPP) for semisolid topical products. Pharmaceutics. 2020;12(3):287.PubMedCentralCrossRef Namjoshi S, Dabbaghi M, Roberts MS, Grice JE, Mohammed Y. Quality by design: development of the quality target product profile (QTPP) for semisolid topical products. Pharmaceutics. 2020;12(3):287.PubMedCentralCrossRef
25.
go back to reference Bos J, Meinardi MM. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–9. Bos J, Meinardi MM. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–9.
26.
go back to reference Lye GJ, Stuckey DC. Structure and stability of colloidal liquid aphrons. Colloids Surf A Physiochem Eng Asp. 2016;131(1–3):119–36. Lye GJ, Stuckey DC. Structure and stability of colloidal liquid aphrons. Colloids Surf A Physiochem Eng Asp. 2016;131(1–3):119–36.
27.
go back to reference Ward K, Cortés JGC, Stuckey DA-O. Alginate as a support ligand for enhanced colloidal liquid aphron immobilization of proteins and drug delivery. Biotechnol Bioeng. 2018;116(12):3168–78.CrossRef Ward K, Cortés JGC, Stuckey DA-O. Alginate as a support ligand for enhanced colloidal liquid aphron immobilization of proteins and drug delivery. Biotechnol Bioeng. 2018;116(12):3168–78.CrossRef
28.
go back to reference Wilhelm KP, Surber C, Maibach HI. Effect of sodium lauryl sulfate-induced skin irritation on in vivo percutaneous penetration of four drugs. J Invest Dermatol. 1991;97(5):927–32.PubMedCrossRef Wilhelm KP, Surber C, Maibach HI. Effect of sodium lauryl sulfate-induced skin irritation on in vivo percutaneous penetration of four drugs. J Invest Dermatol. 1991;97(5):927–32.PubMedCrossRef
29.
go back to reference MC2 Therapeutics. Diffusion 85 comparison of MC2-01 cream formulations: distribution of actives, reduced number of PADs. Hørsholm: MC2 Therapeutics; 2017. MC2 Therapeutics. Diffusion 85 comparison of MC2-01 cream formulations: distribution of actives, reduced number of PADs. Hørsholm: MC2 Therapeutics; 2017.
30.
go back to reference MC2 Therapeutics. MC2 therapeutics skin flux study 92. Hørsholm: MC2 Therapeutics; 2016. MC2 Therapeutics. MC2 therapeutics skin flux study 92. Hørsholm: MC2 Therapeutics; 2016.
31.
go back to reference Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol JEADV. 2022;36(2):228–36.PubMedCrossRef Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol JEADV. 2022;36(2):228–36.PubMedCrossRef
32.
go back to reference Protopic ointment. European public assessment report - product information. European Medicines Agency. 2022. Protopic ointment. European public assessment report - product information. European Medicines Agency. 2022.
33.
go back to reference CiToxLab. Topical tacrolimus cream—a 4-week local skin tolerance study in minipigs (study ID: 77536; MC2-11-PC01). Évreux: CiToxLab; 2020. CiToxLab. Topical tacrolimus cream—a 4-week local skin tolerance study in minipigs (study ID: 77536; MC2-11-PC01). Évreux: CiToxLab; 2020.
34.
go back to reference Praestegaard M, Steele F, Gomez F. Pharmacokinetic characterization of a novel ocular formulation of ciclosporin. Investig Ophthalmol Visual Sci. 2016;57(12):5388. Praestegaard M, Steele F, Gomez F. Pharmacokinetic characterization of a novel ocular formulation of ciclosporin. Investig Ophthalmol Visual Sci. 2016;57(12):5388.
35.
go back to reference EC. Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668). Brussels: EC; 2019. EC. Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668). Brussels: EC; 2019.
36.
go back to reference Lebwohl M, Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis. 2005;76(6 Suppl):7–12.PubMed Lebwohl M, Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis. 2005;76(6 Suppl):7–12.PubMed
37.
go back to reference Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020;84(2):432–70. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020;84(2):432–70.
38.
go back to reference Maul JT, Anzengruber F, Conrad C, Cozzio A, Häusermann P, Jalili A, et al. Topical treatment of Psoriasis vulgaris: the Swiss Treatment Pathway. Dermatology. 2021;237(2):166–78.PubMedCrossRef Maul JT, Anzengruber F, Conrad C, Cozzio A, Häusermann P, Jalili A, et al. Topical treatment of Psoriasis vulgaris: the Swiss Treatment Pathway. Dermatology. 2021;237(2):166–78.PubMedCrossRef
39.
go back to reference Körber A, Wilsmann-Theis D, Augustin M, von Kiedrowski R, Mrowietz U, Rosenbach T, et al. Topische Therapie bei Psoriasis vulgaris—ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3–14. Körber A, Wilsmann-Theis D, Augustin M, von Kiedrowski R, Mrowietz U, Rosenbach T, et al. Topische Therapie bei Psoriasis vulgaris—ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3–14.
40.
go back to reference Triangle Insights Group. Primary and secondary qualitative and quantitative research of positioning of MC2-01 PAD-cream for psoriasis. Durham: Triangle Insights Group; 2017. Triangle Insights Group. Primary and secondary qualitative and quantitative research of positioning of MC2-01 PAD-cream for psoriasis. Durham: Triangle Insights Group; 2017.
41.
go back to reference Kornmehl H, Callis Duffin K, Salame N, Perez-Chada LM, Singh S, Garg A, et al. Examination of treatment satisfaction instruments in psoriasis: 2017 results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). Dermatology. 2021;237(2):151–7.PubMedCrossRef Kornmehl H, Callis Duffin K, Salame N, Perez-Chada LM, Singh S, Garg A, et al. Examination of treatment satisfaction instruments in psoriasis: 2017 results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). Dermatology. 2021;237(2):151–7.PubMedCrossRef
42.
go back to reference Feldman SR, Præstegaard M, Andreasen AH, Selmer J, Holm-Larsen T. Validation of the self-reported psoriasis treatment convenience scale (PTCS). Dermatol Ther (Heidelb). 2021;11(6):2077–88.CrossRef Feldman SR, Præstegaard M, Andreasen AH, Selmer J, Holm-Larsen T. Validation of the self-reported psoriasis treatment convenience scale (PTCS). Dermatol Ther (Heidelb). 2021;11(6):2077–88.CrossRef
43.
go back to reference Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327–32.PubMed Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327–32.PubMed
44.
go back to reference Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K. Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). Arch Dermatol Res. 2014;306(3):287–97.PubMedPubMedCentralCrossRef Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K. Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). Arch Dermatol Res. 2014;306(3):287–97.PubMedPubMedCentralCrossRef
45.
go back to reference Hong CH, Papp KA, Lophaven KW, Skallerup P, Philipp S. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol. 2017;31(11):1876–83.PubMedPubMedCentralCrossRef Hong CH, Papp KA, Lophaven KW, Skallerup P, Philipp S. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol. 2017;31(11):1876–83.PubMedPubMedCentralCrossRef
46.
go back to reference Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–74.PubMedCrossRef Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–74.PubMedCrossRef
47.
go back to reference Hoelker S, Ninosu N, Buettner S, Peitsch WK, Schaarschmidt ML. Patient preferences for topical psoriasis treatments: a discrete choice experiment. J Dermatolog Treat. 2022;33(5):2595–604.CrossRefPubMed Hoelker S, Ninosu N, Buettner S, Peitsch WK, Schaarschmidt ML. Patient preferences for topical psoriasis treatments: a discrete choice experiment. J Dermatolog Treat. 2022;33(5):2595–604.CrossRefPubMed
48.
go back to reference Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61–7.PubMedCrossRef Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61–7.PubMedCrossRef
49.
go back to reference Tier HL, Balogh EA, Bashyam AM, Fleischer AB Jr, Spergel JM, Masicampo EJ, et al. Tolerability of and adherence to topical treatments in atopic dermatitis: a narrative review. Dermatol Ther (Heidelb). 2021;11(2):415–31.CrossRef Tier HL, Balogh EA, Bashyam AM, Fleischer AB Jr, Spergel JM, Masicampo EJ, et al. Tolerability of and adherence to topical treatments in atopic dermatitis: a narrative review. Dermatol Ther (Heidelb). 2021;11(2):415–31.CrossRef
50.
go back to reference Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014;94(1):46–53.PubMed Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014;94(1):46–53.PubMed
51.
go back to reference Figenshau K, Kimmis BD, Reicherter P. Variations in preference for topical vehicles among demographic groups. Cutis. 2020;106(1):40–3.PubMedCrossRef Figenshau K, Kimmis BD, Reicherter P. Variations in preference for topical vehicles among demographic groups. Cutis. 2020;106(1):40–3.PubMedCrossRef
52.
go back to reference Lind M, Nielsen KT, Schefe LH, Nørremark K, Eriksson AH, Norsgaard H, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413–25.CrossRef Lind M, Nielsen KT, Schefe LH, Nørremark K, Eriksson AH, Norsgaard H, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413–25.CrossRef
53.
go back to reference Menter A, Gold LS, Koo J, Villumsen J, Rosen M, Lebwohl M. Fixed-combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with Psoriasis vulgaris: pooled data from three randomized controlled studies. Skinmed. 2017;15(2):119–24.PubMed Menter A, Gold LS, Koo J, Villumsen J, Rosen M, Lebwohl M. Fixed-combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with Psoriasis vulgaris: pooled data from three randomized controlled studies. Skinmed. 2017;15(2):119–24.PubMed
54.
go back to reference Reich A, Selmer J, Galván J, Trebbien P, Pi-Blanque A, Danø A, et al. Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis. Curr Med Res Opin. 2022;38(9):1521–9.CrossRefPubMed Reich A, Selmer J, Galván J, Trebbien P, Pi-Blanque A, Danø A, et al. Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis. Curr Med Res Opin. 2022;38(9):1521–9.CrossRefPubMed
55.
go back to reference Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51(4):515–25.PubMedCrossRef Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51(4):515–25.PubMedCrossRef
56.
go back to reference Yamanaka M, Yokota S, Iwao Y, Noguchi S, Itai S. Development and evaluation of a tacrolimus cream formulation using a binary solvent system. Int J Pharm. 2014;464(1–2):19–26.PubMedCrossRef Yamanaka M, Yokota S, Iwao Y, Noguchi S, Itai S. Development and evaluation of a tacrolimus cream formulation using a binary solvent system. Int J Pharm. 2014;464(1–2):19–26.PubMedCrossRef
57.
go back to reference Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212–6.PubMedCrossRef Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212–6.PubMedCrossRef
58.
go back to reference Carroll C, Feldman S, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895–7.PubMedCrossRef Carroll C, Feldman S, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895–7.PubMedCrossRef
59.
go back to reference Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in Psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015;29(12):2349–55.PubMedPubMedCentralCrossRef Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in Psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015;29(12):2349–55.PubMedPubMedCentralCrossRef
60.
go back to reference Queille-Roussel C, Hoffmann V, Ganslandt C, Hansen KK. Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of Psoriasis vulgaris using a modified psoriasis plaque test. Clin Drug Investig. 2012;32(9):613–9.PubMed Queille-Roussel C, Hoffmann V, Ganslandt C, Hansen KK. Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of Psoriasis vulgaris using a modified psoriasis plaque test. Clin Drug Investig. 2012;32(9):613–9.PubMed
61.
go back to reference Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263–71.PubMedCrossRef Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263–71.PubMedCrossRef
62.
go back to reference Simonsen L, Hoy G, Didriksen E, Persson J, Melchior N, Hansen J. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm. 2004;30(10):1095–102.PubMedCrossRef Simonsen L, Hoy G, Didriksen E, Persson J, Melchior N, Hansen J. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm. 2004;30(10):1095–102.PubMedCrossRef
63.
go back to reference Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420–5.PubMedCrossRef Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420–5.PubMedCrossRef
64.
go back to reference Iris Pharma. Study report: pilot ocular pharmacokinetic study of PAD formulations following a single topical ocular administration in pigmented rabbit (study ID: M59K24412). La Gaude: France; 2013. Iris Pharma. Study report: pilot ocular pharmacokinetic study of PAD formulations following a single topical ocular administration in pigmented rabbit (study ID: M59K24412). La Gaude: France; 2013.
65.
go back to reference CiToxLab. Study report: calcipotriene/betametasone cream: a 8-week toxicity study in minipigs (study ID 76232; MC2-01-PC02). Évreux: CiToxLab; 2015. CiToxLab. Study report: calcipotriene/betametasone cream: a 8-week toxicity study in minipigs (study ID 76232; MC2-01-PC02). Évreux: CiToxLab; 2015.
Metadata
Title
Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application
Authors
Morten Praestegaard
Fraser Steele
Nigel Crutchley
Publication date
01-09-2022
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 10/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-022-00794-y

Other articles of this Issue 10/2022

Dermatology and Therapy 10/2022 Go to the issue